Creating Continuity from Phase I Through Registration

Starting a sponsor relationship early can create greater continuity throughout clinical development. In this discussion, the leaders explain how Caidya and Simbec-Orion can support programs beginning with first-in-human and first-in-patient studies, including early oncology development, and continue through Phase II, Phase III, and registration. Simbec-Orion’s clinical pharmacology capabilities provide an early entry point into development, while the combined organization can maintain greater continuity in teams, databases, processes, and quality as programs advance. This connected approach allows Caidya and Simbec-Orion to build longer-term sponsor partnerships while supporting a clinical program from its earliest human studies through later-stage development.